Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1987 Dec;28(4):839-44.
doi: 10.1002/ajmg.1320280408.

Plasma immunoreactive beta-melanocyte stimulating hormone (lipotropin) levels in individuals with Prader-Labhart-Willi syndrome

Affiliations

Plasma immunoreactive beta-melanocyte stimulating hormone (lipotropin) levels in individuals with Prader-Labhart-Willi syndrome

M G Butler et al. Am J Med Genet. 1987 Dec.

Abstract

Plasma immunoreactive beta-melanocyte-stimulating hormone (beta-MSH) levels, which actually represent the combined concentrations of beta-lipotropin (beta-LPH) and gamma-LPH in normal individuals, were measured in 12 patients (6 males and 6 females with an average age of 16.8 years, range 4 months to 27 years) with the Prader-Labhart-Willi syndrome (PLWS). Five patients were previously identified with high-resolution analysis as having the 15q chromosomal deletion, whereas 7 patients had normal chromosomes. Hypopigmentation was observed in all 5 patients with the 15q deletion. Of the 7 individuals with normal chromosomes, two were hypopigmented and 5 had normal pigmentation. Fasting (6 to 12 hours) plasma samples were analyzed for immunoreactive beta-MSH in the 12 PLWS individuals. Plasma immunoreactive beta-MSH (LPH) levels were within the normal range in all 12 individuals. There was no significant difference in the plasma immunoreactive beta-MSH concentrations between patients who did and did not have the chromosomal deletion or in those who were or were not hypopigmented. Thus, a decrease in circulating plasma immunoreactive beta-MSH (LPH) does not appear to be the cause of the hypopigmentation observed in some patients with PLWS.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Abe K, Island DP, Liddle GW, Fleischer N, Nicholson WE (1967): Radioimmunologic evidence for a-MSH (melanocyte stimulating hormone) in human pituitary and tumor tissues. J Clin Endocrinol Metab 27:46–52. - PubMed
    1. Bloomfield GA, Scott AP, Lowry PJ, Gilkes JJH, Rees LH (1974): A reappraisal of human β MSH. Nature (Lond) 252:492–493. - PubMed
    1. Butler MG, Meaney FJ, Palmer CG (1986): Clinical and cytogenetic survey of 39 individuals with Prader-Labhart-Willi syndrome. Am J Med Genet 23:793–809. - PMC - PubMed
    1. Carter RJ, Shuster S (1979): β-endorphin potentiates melanocyte-stimulating activity on the skin of Anolis carolinensis. J Endocrinol 80:7P (Abstract). - PubMed
    1. Carter RJ, Shuster S, Morley JS (1979): Melanotropin potentiating factor is the C-terminal tetrapeptide of human β-lipotropin. Nature (Lond) 279:74–75. - PubMed

Publication types

Substances